NCT05837260 Investigating Utility of ctDNA and Tumour Evolution in Advanced Thyroid Cancer
| NCT ID | NCT05837260 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Royal Marsden NHS Foundation Trust |
| Condition | Thyroid Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2023-03-23 |
| Primary Completion | 2027-02-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2023-03-23 with a primary completion date of 2027-02-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Although most thyroid cancers are treated and cured successfully there are still 30% who recur after many years. This will eventually progress and at this point may become incurable with treatment options including complex and high risk surgery. The overall efficacy of systemic treatment in advanced thyroid cancer has a good initial response in most patients but not all. The study will collect tissues and blood samples for various protein analysis, nucleic acid extraction and live cell analysis in order to try and detect the presence of plasma ctDNA at baseline of eligible patients.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older. (all cohorts) * Patients diagnosed with radioiodine refractory differentiated thyroid carcinoma (RR-DTC) under surveillance. (cohort 1) * Patients with newly diagnosed resectable locally advanced medullary thyroid cancer Or Patients with newly diagnosed metastatic medullary thyroid cancer for surveillance Or Patients with locally advanced or metastatic medullary thyroid cancer on surveillance (cohort 2) * Patients with RR-DTC starting systemic therapy Or Patients with RR-DTC on systemic therapy Or Patients with MTC starting systemic therapy Or Patients with MTC on systemic therapy (cohort 3) * Patients with newly diagnosed anaplastic thyroid cancer (cohort 4) * Availability of tissue from one archival diagnostic tumour tissue block or be willing to have biopsy of accessible disease (all cohorts) * Patients must be willing to undergo standard monitoring and treatment as recommended by their clinical team (all cohorts) * Ability to give inform
Frequently Asked Questions
Who can join the NCT05837260 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05837260 currently recruiting?
Yes, NCT05837260 is actively recruiting participants. Visit ClinicalTrials.gov or contact Royal Marsden NHS Foundation Trust to inquire about joining.
Where is the NCT05837260 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT05837260 clinical trial?
NCT05837260 is sponsored by Royal Marsden NHS Foundation Trust. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.